Single nucleotide polymorphisms of the IL10 gene have been linked to the occurrence of autoimmune liver disease.
Methods:
We performed a meta-analysis to assess the association between three IL10 promoter polymorphisms (rs1800896, rs1800871, and rs1800872) and the risk of autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis.
Results:
In total, 1420 articles were initially identified through database retrieval. After screening, seven eligible articles were ultimately included in the meta-analysis. A fixed-effect model was used for all Mantel-Haenszel statistics due to the absence of large between-study heterogeneity (all I2 < 50%, p > 0.1). No association between any of the studied polymorphisms and risk of autoimmune liver disease was detected in the allele, homozygote, heterozygote, dominant, recessive, or carrier genetic models (passociation > 0.05). Potential publication bias was excluded using Begg's and Egger's tests. Similar negative results were observed in subgroup analyses and in an analysis of the three haplotypes of rs1800896/rs1800871/rs1800872 (G/C/C, A/C/C, and A/T/A).
Conclusion:
Our meta-analysis strongly suggests that the IL10 rs1800896, rs1800871, and rs1800872 polymorphisms are not associated with the risk of autoimmune liver disease.
Get full access to this article
View all access options for this article.
References
1.
AizawaY, HokariA (2017) Autoimmune hepatitis: current challenges and future prospects. Clin Exp Gastroenterol, 10:9-18.
2.
BathgateAJ, PravicaV, PerreyC, et al. (2000) Polymorphisms in tumour necrosis factor alpha, interleukin-10 and transforming growth factor beta1 genes and end-stage liver disease. Eur J Gastroenterol Hepatol, 12:1329-1333.
3.
BenitezJA, ChengS, DengQ (2017) Revealing allele-specific gene expression by single-cell transcriptomics. Int J Biochem Cell Biol, 90:155-160.
4.
ChenQB, FanLY, ZhongRQ, et al. (2004) [A study on the relationship between interleukin-10 promoter polymorphism and autoimmune liver disease]. Zhonghua Gan Zang Bing Za Zhi, 12:356-358.
5.
CooksonS, ConstantiniPK, ClareM, et al. (1999) Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology, 30:851-856.
6.
de BoerYS, van GervenNM, ZwiersA, et al. (2014) Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology, 147:443-452.e5.
7.
DonaldsonPT, NorrisS, ConstantiniPK, et al. (2000) The interleukin-1 and interleukin-10 gene polymorphisms in primary sclerosing cholangitis: no associations with disease susceptibility/resistance. J Hepatol, 32:882-886.
8.
Eskandari-NasabE, TahmasebiA, HashemiM (2015) Meta-analysis: the relationship between CTLA-4 + 49 A/G polymorphism and primary biliary cirrhosis and type I autoimmune hepatitis. Immunol Invest, 44:331-348.
9.
EskdaleJ, KubeD, TeschH, et al. (1997) Mapping of the human IL10 gene and further characterization of the 5′ flanking sequence. Immunogenetics, 46:120-128.
10.
FanLY, TuXQ, ZhuY, et al. (2005) Genetic association of cytokines polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. World J Gastroenterol, 11:2768-2772.
11.
FloreaniA, TanakaA, BowlusC, et al. (2017) Geoepidemiology and changing mortality in primary biliary cholangitis. J Gastroenterol, 52:655-662.
12.
GrantCR, LiberalR (2017) Liver immunology: how to reconcile tolerance with autoimmunity. Clin Res Hepatol Gastroenterol, 41:6-16.
13.
HiguchiT, OkaS, FurukawaH, et al. (2017) Association of a single nucleotide polymorphism upstream of ICOS with Japanese autoimmune hepatitis type 1. J Hum Genet, 62:481-484.
14.
HirschfieldGM, LiuX, XuC, et al. (2009) Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med, 360:2544-2555.
15.
JiSG, JuranBD, MuchaS, et al. (2017) Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet, 49:269-273.
16.
JiangX, KarlsenTH (2017) Genetics of primary sclerosing cholangitis and pathophysiological implications. Nat Rev Gastroenterol Hepatol, 14:279-295.
17.
JoshitaS, UmemuraT, TanakaE, et al. (2017) Genetic contribution to the pathogenesis of primary biliary cholangitis. J Immunol Res, 2017:3073504.
18.
JungJH, SongGG, KimJH, et al. (2016) Association of interleukin 10 gene polymorphisms with autoimmune thyroid disease: meta-analysis. Scand J Immunol, 84:272-277.
19.
KarlsenTH, ChungBK (2015) Genetic risk and the development of autoimmune liver disease. Dig Dis, 33Suppl 2:13-24.
20.
KovacJD, WeberMA (2016) Primary biliary cirrhosis and primary sclerosing cholangitis: an update on MR imaging findings with recent developments. J Gastrointestin Liver Dis, 25:517-524.
21.
LiuL, ZhengF (2016) IL-10 -1082A/G, -592C/A, and -819T/C polymorphisms in association with lung cancer susceptibility: a meta-analysis. Onco Targets Ther, 9:6083-6091.
22.
LiuP, SongJ, SuH, et al. (2013) IL-10 gene polymorphisms and susceptibility to systemic lupus erythematosus: a meta-analysis. PLoS One, 8:e69547.
23.
LiuQ, LiW, LiD, et al. (2015) The association of interleukin-10 -1082, -819, -592 polymorphisms and tuberculosis risk. Saudi Med J, 36:407-417.
24.
MaX, QiuDK (2004) [Cytokine gene polymorphisms in Chinese patients with type I autoimmune hepatitis]. Zhonghua Gan Zang Bing Za Zhi, 12:296-298.
25.
MatsudaK (2017) PCR-based detection methods for single-nucleotide polymorphism or mutation: real-time PCR and its substantial contribution toward technological refinement. Adv Clin Chem, 80:45-72.
26.
MatsushitaM, TanakaA, KikuchiK, et al. (2002) Association of single nucleotide polymorphisms of the interleukin-10 promoter gene and susceptibility to primary biliary cirrhosis: immunogenetic differences in Italian and Japanese patients. Autoimmunity, 35:531-536.
27.
MitchellSA, GroveJ, SpurklandA, et al. (2001) Association of the tumour necrosis factor alpha -308 but not the interleukin 10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut, 49:288-294.
28.
MiyagakiT, FujimotoM, SatoS (2015) Regulatory B cells in human inflammatory and autoimmune diseases: from mouse models to clinical research. Int Immunol, 27:495-504.
29.
MoherD, LiberatiA, TetzlaffJ, et al. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6:e1000097.
30.
QiuF, TangR, ZuoX, et al. (2017) A genome-wide association study identifies six novel risk loci for primary biliary cholangitis. Nat Commun, 8:14828.
31.
SaxenaA, KhosravianiS, NoelS, et al. (2015) Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine, 74:27-34.
32.
StangA (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 25:603-605.
33.
TarabayM, ElshazliR, SettinA (2016) African vs. Caucasian and Asian difference for the association of interleukin-10 promotor polymorphisms with type 2 diabetes mellitus (a meta-analysis study). Meta Gene, 9:10-17.
34.
UmemuraT, JoshitaS, YamazakiT, et al. (2016) Genetic association of PTPN22 polymorphisms with autoimmune hepatitis and primary biliary cholangitis in Japan. Sci Rep, 6:29770.
35.
van GervenNM, de BoerYS, MulderCJ, et al. (2016) Auto immune hepatitis. World J Gastroenterol, 22:4651-4661.
36.
WalterMR (2014) The molecular basis of IL-10 function: from receptor structure to the onset of signaling. Curr Top Microbiol Immunol, 380:191-212.
37.
WebbGJ, HirschfieldGM (2016) Using GWAS to identify genetic predisposition in hepatic autoimmunity. J Autoimmun, 66:25-39.
38.
WeiYG, LiuF, LiB, et al. (2011) Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility: a meta-analysis. World J Gastroenterol, 17:3941-3947.
39.
YeQ, QianBX, YinWL, et al. (2016) Association between the HFE C282Y, H63D polymorphisms and the risks of non-alcoholic fatty liver disease, liver cirrhosis and hepatocellular carcinoma: an updated systematic review and meta-analysis of 5,758 cases and 14,741 controls. PLoS One, 11:e0163423.
40.
ZappalaF, GroveJ, WattFE, et al. (1998) No evidence for involvement of the interleukin-10 -592 promoter polymorphism in genetic susceptibility to primary biliary cirrhosis. J Hepatol, 28:820-823.
41.
ZouL, WangL, GongX, et al. (2014) The association between three promoter polymorphisms of IL-10 and inflammatory bowel diseases (IBD): a meta-analysis. Autoimmunity, 47:27-39.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
